Leveraging the lower BCL-XL dependence of young platelets, stimulation of de novo platelet production with the thrombopoietin receptor agonist romiplostim prevents BH3 mimetic-induced thrombocytopenia in vivo and may prevent severe platelet loss in patients treated with BCL-XL inhibitors. The gene discussed is BCL2L1; the disease is Thrombocytopenia.